Andrew E. Levin
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$20.5MFederal grants as PI33 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
33 awards · $20.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 4, 2026 | NIH | SBIR Phase II Peptide-based ELISA for laboratory diagnosis of sarcoidosis | $1.0M | KEPHERA DIAGNOSTICS LLC |
| Aug 24, 2026 | NIH | SBIR Phase I Rapid Diagnostic Immunoassay for Strongyloidiasis | $303K | KEPHERA DIAGNOSTICS LLC |
| Sep 16, 2025 | NIH | SBIR Phase II Biomarker-Based Test of Cure for Chagas Disease | $906K | KEPHERA DIAGNOSTICS LLC |
| Sep 14, 2025 | NIH | SBIR Phase II Peptide-based ELISA for laboratory diagnosis of sarcoidosis | $978K | KEPHERA DIAGNOSTICS LLC |
| Aug 28, 2025 | NIH | SBIR Phase II Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients | $124K | KEPHERA DIAGNOSTICS LLC |
| Aug 27, 2025 | NIH | SBIR Phase II Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients | $876K | KEPHERA DIAGNOSTICS LLC |
| Aug 27, 2025 | NIH | SBIR Phase I Diagnostic assay for congenital Chagas disease | $303K | KEPHERA DIAGNOSTICS LLC |
| Aug 20, 2025 | NIH | SBIR Phase II Hybrid ELISA: Simple and specific one-tier assay for Lyme disease | $715K | KEPHERA DIAGNOSTICS LLC |
| Apr 11, 2025 | NIH | SBIR Phase II Point-of-care diagnostic test for T. cruzi (Chagas) infection | $1.0M | KEPHERA DIAGNOSTICS LLC |
| Aug 30, 2024 | NIH | SBIR Phase I MiCRIA: Two-minute rapid assay platform for point-of-care diagnosis | $303K | KEPHERA DIAGNOSTICS LLC |
| Jul 31, 2024 | NIH | SBIR Phase II Hybrid ELISA: Simple and specific one-tier assay for Lyme disease | $1.0M | KEPHERA DIAGNOSTICS LLC |
| Jul 29, 2024 | NIH | SBIR Phase II Biomarker-Based Test of Cure for Chagas Disease | $1.0M | KEPHERA DIAGNOSTICS LLC |
| Apr 26, 2024 | NIH | SBIR Phase I Diagnostic assay for congenital Chagas disease | $303K | KEPHERA DIAGNOSTICS LLC |
| Apr 5, 2024 | NIH | SBIR Phase II Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients | $1.0M | KEPHERA DIAGNOSTICS LLC |
| Apr 1, 2024 | NIH | SBIR Phase I Development of an ELISA for serosurveillance of human hookworm | $300K | KEPHERA DIAGNOSTICS LLC |
| Mar 27, 2024 | NIH | SBIR Phase II Point-of-care diagnostic test for T. cruzi (Chagas) infection | $1.0M | KEPHERA DIAGNOSTICS LLC |
| Sep 11, 2023 | NIH | SBIR Phase II Hybrid ELISA: Simple and specific one-tier assay for Lyme disease | $1.0M | KEPHERA DIAGNOSTICS LLC |
| Sep 5, 2023 | NIH | SBIR Phase II Biomarker-Based Test of Cure for Chagas Disease | $1.0M | KEPHERA DIAGNOSTICS LLC |
| May 12, 2023 | NIH | SBIR Phase II Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients | $999K | KEPHERA DIAGNOSTICS LLC |
| Mar 30, 2023 | NIH | SBIR Phase II Point-of-care diagnostic test for T. cruzi (Chagas) infection | $1.0M | KEPHERA DIAGNOSTICS LLC |
| Mar 27, 2023 | NIH | SBIR Phase I Development of an ELISA for serosurveillance of human hookworm | $300K | KEPHERA DIAGNOSTICS LLC |
| Jul 15, 2021 | NIH | SBIR Phase II Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling | $989K | KEPHERA DIAGNOSTICS LLC |
| Dec 11, 2020 | NIH | SBIR Phase I Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients | $300K | KEPHERA DIAGNOSTICS LLC |
| Jul 22, 2020 | NIH | SBIR Phase II Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling | $1.0M | KEPHERA DIAGNOSTICS LLC |
| Jul 9, 2020 | NIH | SBIR Phase I Biomarker-Based Test of Cure for Chagas Disease | $300K | KEPHERA DIAGNOSTICS LLC |
| Feb 19, 2020 | NIH | SBIR Phase I Hybrid ELISA: Simple and specific one-tier assay for Lyme disease | $300K | KEPHERA DIAGNOSTICS LLC |
| Jan 10, 2020 | NIH | SBIR Phase I Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients | $300K | KEPHERA DIAGNOSTICS LLC |
| Jul 16, 2019 | NIH | SBIR Phase I Biomarker-Based Test of Cure for Chagas Disease | $300K | KEPHERA DIAGNOSTICS LLC |
| Jun 27, 2019 | NIH | SBIR Phase I Point-of-care diagnostic test for T. cruzi (Chagas) infection | $299K | KEPHERA DIAGNOSTICS LLC |
| Mar 5, 2019 | NIH | SBIR Phase I Hybrid ELISA: Simple and specific one-tier assay for Lyme disease | $300K | KEPHERA DIAGNOSTICS LLC |
| Aug 7, 2018 | NIH | SBIR Phase I Point-of-care diagnostic test for T. cruzi (Chagas) infection | $300K | KEPHERA DIAGNOSTICS LLC |
| Jul 13, 2018 | NIH | SBIR Phase I Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling | $299K | KEPHERA DIAGNOSTICS LLC |
| Aug 18, 2017 | NIH | SBIR Phase I Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling | $300K | KEPHERA DIAGNOSTICS LLC |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#10
Awards as PI#4
Patents#505
Companies
- KEPHERA DIAGNOSTICS LLCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.